RIDDLE&CODE
RIDDLE&CODE FinTech Solutions, an innovative European company that empowers financial institutions to handle all aspects of digital asset management, announced today that LiteBit, the leading Dutch cryptocurrency exchange, has chosen its Token Management Platform (TMP) to scale infrastructure, respond to regulatory requirements and provide advanced capabilities to its growing customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005034/en/
Over the last few years, the European Union has significantly tightened its regulations on crypto service providers, including the recently updated 5th Anti-Money Laundering Directive (AMLD5). The newly implemented AMLD5 guidelines oblige service providers such as crypto exchanges and custodians to adhere to the same regulatory provisions as traditional financial institutions.
“The Dutch implementation of the regulations currently goes beyond EU guidelines and calls for extensive identification of customers and monitoring of transactions as well as extensive reporting and audit capabilities,” said Berit Fuss, Director of FinTech Solutions at RIDDLE&CODE. “These requirements have turned out to be quite burdensome and have forced several crypto-related businesses to close or leave the Netherlands.”
“Crypto exchanges across the industry are prioritising compliance with regulatory obligations. LiteBit is no exception,” said Arthur Van Lier, LiteBit’s COO. “The partnership with RIDDLE&CODE and the use of the cutting-edge TMP enables us to be compliant with both current and future regulations. But regulatory frameworks aren’t the only ones evolving,” he added. “At the moment, Decentralised Finance (DeFi) is one of the fastest-growing sectors in the crypto industry. However, due to the complexity of the applications and the efforts required to support several token protocols, many market players struggle to innovate and accommodate the integration of DeFi capabilities. With the TMP, we can benefit from these new business models and scale our operational capabilities.”
The TMP provides the Dutch exchange with a robust and transparent foundation for:
- Responding to the most pressing demands in an ever-changing regulatory environment, including AML/CFT requirements, customer due diligence, Know-Your-Customer (KYC) procedures and more.
- Scaling its operations by creating unlimited segregated accounts for its customers and automating certain processes to reduce the burden on the operational teams.
- Being flexible enough to offer DeFi services such as staking or voting on popular networks like Polkadot and Ethereum.
The Token Management Platform is the next generation of RIDDLE&CODE’s institutional-grade digital asset management solution. The cloud-based platform manages all aspects of key generation, custody, AML, regulatory compliance and token management. Accepted by the Swiss financial market authorities, the TMP is fully auditable and compliant with financial regulations, allowing clients to fulfill all transparency requirements in line with financial regulations and internal compliance policies.
“We are thrilled to work with LiteBit, our first crypto exchange customer,” said Alexander Koppel, CEO of RIDDLE&CODE. “This strategic partnership allows us to enter the Dutch market and help LiteBit in its journey to full regulatory compliance and expansion across Europe.”
RIDDLE&CODE FinTech Solutions
RIDDLE&CODE FinTech solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, builds hardware and software stacks that empower funds, crypto exchanges and regulated financial institutions to manage all aspects of key generation, custody, AML, regulatory compliance and token management with unmatched versatility and security.
LiteBit
LiteBit is a platform that makes trading in crypto safe, simple and personal. Its aim is to be the most customer-friendly and reliable platform in Europe. LiteBit supports investors in buying, selling and managing crypto, such as Bitcoin, Ethereum and more than 50 other types of coins.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom